Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas

Clinical Colorectal Cancer

Volumn 15, Issue 4, 2016, Pages 345-351

  Pishvaian, Michael ^a   Morse, Michael A ^b   McDevitt, Jennifer ^c   Norton, Jonathan D ^c   Ren, Song ^c   Robbie, Gabriel J ^c   Ryan, Patricia C ^c   Soukharev, Serguei ^c   Bao, Haifeng ^c   Denlinger, Crystal S ^d  

^a GEORGETOWN UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c MEDIMMUNE   (United States)

^d FOX CHASE CANCER CENTER   (United States)

Author keywords

Bispecific antibodies; Clinical trial; Gastrointestinal cancer; Pancreatic cancer; Pharmacokinetics

Indexed keywords

ALANINE AMINOTRANSFERASE; CARCINOEMBRYONIC ANTIGEN; DEXAMETHASONE; DRUG ANTIBODY; MEDI 565; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; CD3 ANTIGEN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTIBODY TITER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACKACHE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; CONSTIPATION; CYTOKINE RELEASE SYNDROME; DIARRHEA; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG HALF LIFE; DYSPNEA; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL CARCINOMA; HEADACHE; HUMAN; HYPERTENSION; HYPOXIA; IMMUNOGENICITY; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OPEN STUDY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; TREATMENT DURATION; VOMITING; ADENOCARCINOMA; CLINICAL TRIAL; DRUG EFFECTS; GASTROINTESTINAL NEOPLASMS; IMMUNOLOGY; IMMUNOTHERAPY; MIDDLE AGED; PROCEDURES; T LYMPHOCYTE;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, BISPECIFIC; ANTIGENS, CD3; ANTINEOPLASTIC AGENTS; CARCINOEMBRYONIC ANTIGEN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; IMMUNOTHERAPY; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; SINGLE-CHAIN ANTIBODIES; T-LYMPHOCYTES;

EID: 84996799341     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2016.07.009     Document Type: Article

References (8)

1. 1 Hammarstrom, S., The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 9 (1999), 67–81.
2. 2 Gold, P., Freedman, S.O., Specific carcinoembryonic antigens of the human digestive system. J Exp Med 122 (1965), 467–481.
3. 3 Lutterbuese, R., Raum, T., Kischel, R., et al. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA. J Immunother 32 (2009), 341–352.
4. 4 Osada, T., Hsu, D., Hammond, S., et al. Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody. Br J Cancer 102 (2010), 124–133.
5. 5 Oberst, M.D., Fuhrmann, S., Mulgrew, K., et al. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas. MAbs 6 (2014), 1571–1584.
6. 6 Waaijer, S.J.H., Warnders, F.J., Lub-de Hooge, M.N., et al. Preclinical evaluation of the radiolabeled bispecific T-cell engager 89Zr-AMG 211 targeting CEA-positive tumors. [abstract A85] Mol Cancer Ther, 14(suppl 2), 2015, A85.
7. 7 Blincyto [package insert], 2014, Amgen Inc, Thousand Oaks, CA.
8. 8 De Vries, E., Heinemann, V., Fiedler, W.M., et al. Phase I study of AMG 211/MEDI565 administered as continuous intravenous infusion for relapsed/refractory gastrointestinal (GI) adenocarcinoma. [abstract] J Clin Oncol, 33(suppl), 2015 (abstract TPS3097).